|
1
|
Tzouvelekis LS, Markogiannakis A,
Psichogiou M, Tassios PT and Daikos GL: Carbapenemases in
Klebsiella pneumoniae and other Enterobacteriaceae: An evolving
crisis of global dimensions. Clin Microbiol Rev. 25:682–707. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Duin D, Kaye KS, Neuner EA and Bonomo
RA: Carbapenem-resistant Enterobacteriaceae: A review of treatment
and outcomes. Diagn Microbiol Infect Dis. 75:115–120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qureshi ZA, Paterson DL, Potoski BA,
Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM and
Doi Y: Treatment outcome of bacteremia due to KPC-producing
Klebsiella pneumoniae: Superiority of combination antimicrobial
regimens. Antimicrob Agents Chemother. 56:2108–2113. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Borer A, Saidel-Odes L, Riesenberg K,
Eskira S, Peled N, Nativ R, Schlaeffer F and Sherf M: Attributable
mortality rate for carbapenem-resistant Klebsiella pneumoniae
bacteremia. Infect Control Hosp Epidemiol. 30:972–976. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carmeli Y, Akova M, Cornaglia G, Daikos
GL, Garau J, Harbarth S, Rossolini GM, Souli M and Giamarellou H:
Controlling the spread of carbapenemase-producing Gram-negatives:
Therapeutic approach and infection control. Clin Microbiol Infect.
16:102–111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee GC and Burgess DS: Treatment of
Klebsiella pneumoniae carbapenemase (KPC) infections: A review of
published case series and case reports. Ann Clin Microbiol
Antimicrob. 11:322012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ni W, Wei C, Zhou C, Zhao J, Liang B, Cui
J, Wang R and Liu Y: Tigecycline-amikacin combination effectively
suppresses the selection of resistance in clinical isolates of
KPC-producing Klebsiella pneumoniae. Front Microbiol. 7:13042016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lewis RE: Using carbapenems for
carbapenem-resistant Klebsiella pneumoniae - are we flogging a dead
(work) horse antibiotic? Virulence. 3:1–2. 2016.
|
|
9
|
Daikos GL and Markogiannakis A:
Carbapenemase-producing Klebsiella pneumoniae: (When) might we
still consider treating with carbapenems? Clin Microbiol Infect.
17:1135–1141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zarkotou O, Pournaras S, Tselioti P,
Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki
K and Tsakris A: Predictors of mortality in patients with
bloodstream infections caused by KPC-producing Klebsiella
pneumoniae and impact of appropriate antimicrobial treatment. Clin
Microbiol Infect. 17:1798–1803. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pournaras S, Vrioni G, Neou E, Dendrinos
J, Dimitroulia E, Poulou A and Tsakris A: Activity of tigecycline
alone and in combination with colistin and meropenem against
Klebsiella pneumoniae carbapenemase (KPC)-producing
Enterobacteriaceae strains by time-kill assay. Int J Antimicrob
Agents. 37:244–247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bratu S, Landman D, Haag R, Recco R, Eramo
A, Alam M and Quale J: Rapid spread of carbapenem-resistant
Klebsiella pneumoniae in New York City: A new threat to our
antibiotic armamentarium. Arch Intern Med. 165:1430–1435. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gasink LB, Edelstein PH, Lautenbach E,
Synnestvedt M and Fishman NO: Risk factors and clinical impact of
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect
Control Hosp Epidemiol. 30:1180–1185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marchaim D, Chopra T, Perez F, Hayakawa K,
Lephart PR, Bheemreddy S, Blunden C, Hujer AM, Rudin S, Shango M,
et al: Outcomes and genetic relatedness of carbapenem-resistant
enterobacteriaceae at Detroit medical center. Infect Control Hosp
Epidemiol. 32:861–871. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirsch EB and Tam VH: Detection and
treatment options for Klebsiella pneumoniae carbapenemases (KPCs):
An emerging cause of multidrug-resistant infection. J Antimicrob
Chemother. 65:1119–1125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gonzalez-Padilla M, Torre-Cisneros J,
Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A,
Natera C, Rodriguez M, Salcedo I, Rodriguez-López F, et al:
Gentamicin therapy for sepsis due to carbapenem-resistant and
colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother.
70:905–913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tumbarello M, Viale P, Viscoli C,
Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S,
Ginocchio F, Cristini F, et al: Predictors of mortality in
bloodstream infections caused by Klebsiella pneumoniae
carbapenemase-producing K. pneumoniae: Importance of combinational
therapy. Clin Infect Dis. 55:943–950. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qureshi ZA, Paterson DL, Peleg AY,
Adams-Haduch JM, Shutt KA, Pakstis DL, Sordillo E, Polsky B,
Sandkovsky G, Bhussar MK and Doi Y: Clinical characteristics of
bacteraemia caused by extended-spectrum β-lactamase-producing
Enterobacteriaceae in the era of CTX-M-type and KPC-type
β-lactamases. Clin Microbiol Infect. 18:887–893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Zheng B, Li Y, Zhu S, Xue F and Liu
J: Antimicrobial susceptibility and molecular mechanisms of
fosfomycin resistance in clinical Escherichia coli isolates in
mainland China. PLoS One. 10:e01352692015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raz R: Fosfomycin: An old - new
antibiotic. Clin Microbiol Infect. 18:4–7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brown ED, Vivas EI, Walsh CT and Kolter R:
MurA (MurZ), the enzyme that catalyzes the first committed step in
peptidoglycan biosynthesis, is essential in Escherichia coli. J
Bacteriol. 177:4194–4197. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yılmaz N, Ağuş N, Bayram A, Şamlıoğlu P,
Şirin MC, Derici YK and Hancı SY: Antimicrobial susceptibilities of
Escherichia coli isolates as agents of community-acquired urinary
tract infection (2008–2014). Turk J Urol. 42:32–36. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Falagas ME, Kastoris AC, Kapaskelis AM and
Karageorgopoulos DE: Fosfomycin for the treatment of
multidrug-resistant, including extended-spectrum beta-lactamase
producing, Enterobacteriaceae infections: A systematic review.
Lancet Infect Dis. 10:43–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roussos N, Karageorgopoulos DE, Samonis G
and Falagas ME: Clinical significance of the pharmacokinetic and
pharmacodynamic characteristics of fosfomycin for the treatment of
patients with systemic infections. Int J Antimicrob Agents.
34:506–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cho YH, Jung SI, Chung HS, Yu HS, Hwang
EC, Kim SO, Kang TW, Kwon DD and Park K: Antimicrobial
susceptibilities of extended-spectrum beta-lactamase-producing
Escherichia coli and Klebsiella pneumoniae in health
care-associated urinary tract infection: focus on susceptibility to
fosfomycin. Int Urol Nephrol. 47:1059–1066. 2014. View Article : Google Scholar
|
|
26
|
Liu CY, Lai CC, Lee MR, Lee YC, Huang YT,
Liao CH and Hsueh PR: Clinical characteristics of infections caused
by Tsukamurella spp. and antimicrobial susceptibilities of the
isolates. Int J Antimicrob Agents. 38:534–537. 2011. View Article : Google Scholar : PubMed/NCBI
|
